Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl- phenylalanine) nanocarrier uptake by macrophages

Bioconjugate Chemistry

Volumn 19, Issue 1, 2008, Pages 28-38

  Wan, Li ^a   Zhang, Xiaoping ^a   Pooyan, Shahriar ^a   Palombo, Matthew S ^a   Leibowitz, Michael J ^b,c   Stein, Stanley ^a   Sinko, Patrick J ^a,c,d  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; DRUG THERAPY; MOLECULAR WEIGHT; PEPTIDES;

ANTI-HIV; COPY NUMBER; COVALENT ATTACHMENT; HIV-1 INFECTIONS; NANOCARRIER UPTAKES; NANOCARRIERS; NOVEL PEPTIDES; REBOUND-EFFECT; RESERVOIR SITES; THERAPEUTIC AGENTS;

MACROPHAGES;

FORMYLMETHIONYLLEUCYLPHENYLALANINE; MACROGOL; NANOCARRIER; POLYETHYLENE GLYCOL N FORMYLMETHIONYLLEUCYLPHENYLALANINE CONJUGATE; UNCLASSIFIED DRUG;

ARTICLE; CONJUGATION; COVALENT BOND; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; MOLECULAR WEIGHT; NONHUMAN;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 38949216354     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc070066k     Document Type: Article

References (35)

1. Vandamme, A. M., Van Vaerenbergh, K., and De Clercq, E. (1998) Anti-human immunodeficiency virus drug combination strategies. Antiviral Chem. Chemother. 9, 187-203.
2. Bangsberg, D. R., Hecht, F. M., Charlebois, E. D., Zolopa, A. R., Holodniy, M., Sheiner, L., Bamberger, J. D., Chesney, M. A., and Moss, A. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14, 357-66.
3. Schrager, L. K., and D'Souza, M. P. (1998) Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy JAMA 280, 67-71.
4. Richman, D. D. (2001) HIV chemotherapy. Nature 410, 995-1001.
5. Schuitemaker, H., Kootstra, N. A., de Goede, R. E., de Wolf, F., Miedema, F., and Tersmette, M. (1991) Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 65, 356-363.
6. Roos, M. T., Lange, J. M., de Goede, R. E., Coutinho, R. A., Schellekens, P. T., Miedema, F., and Tersmette, M. (1992) Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 165, 427-432.
7. Connor, R. I., Paxton, W. A., Sheridan, K. E., and Koup, R. A. (1996) Macrophages and CD4+ T lymphocytes from two multiply exposed, uninfected individuals resist infection with primary non-syncytium-inducing isolates of human immunodeficiency virus type 1. J. Virol. 70, 8758-8764.
8. Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., and Landau, N. R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377.
9. Aquaro, S., Calio, R., Balzarini, J., Bellocchi, M. C., Garaci, E., and Perno, C. F. (2002) Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res. 55, 209.
10. Fridkin, M., Tsubery, H., Tzehoval, E., Vonsover, A., Biondi, L., Filira, F., and Rocchi, R. (2005) Tuftsin-AZT conjugate: potential macrophage targeting for AIDS therapy. J Pept Sci 11, 37-44.
11. Hu, J., Liu, H., and Wang, L. (2000) Enhanced delivery of AZT to macrophages via acetylated LDL. J. Controlled Release 69, 327-335.
12. Le, Y., Yang, Y., Cui, Y., Yazawa, H., Gong, W., Qiu, C., and Wang, J. M. (2002) Receptors for chemotactic formyl peptides as pharmacological targets. Int. Immunopharmacol. 2, 1-13.
13. Niedel, J. E., Kahane, I., and Cuatrecasas, P. (1979) Receptor-mediated internalization of fluorescent chemotactic peptide by human neutrophils. Science 205, 1412-1414.
14. van Eerd, J. E., Boerman, O. C., Corstens, F. H., and Oyen, W. J. (2003) Radiolabeled chemotactic cytokines: new agents for scintigraphic imaging of infection and inflammation. Q. J. Nucl. Med. 47, 246-255.
15. Pooyan, S., Qiu, B., Chan, M. M., Fong, D., Sinko, P. J., Leibowitz, M. J., and Stein, S. (2002) Conjugates bearing multiple formyl-methionyl peptides display enhanced binding to but not activation of phagocytic cells. Bioconjugate Chem, 13, 216-221.
16. Fischer, D. G., Pike, M. C., Koren, H. S., and Snyderman, R. (1980) Chemotactically responsive and nonresponsive forms of a continuous human monocyte cell line. J. Immunol. 125, 463-465.
17. Pike, M. C., Fischer, D. G., Koren, H. S., and Snyderman, R. (1980) Development of specific receptors for N-formylated chemotactic peptides in a human monocyte cell line stimulated with lymphokines. J. Exp. Med. 152, 31-40.
18. Prossnitz, E. R., and Ye, R. D. (1997) The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. Pharmacol. Ther. 74, 73-102.
19. Kozlowski, A., and Harris, J. M. (2001) Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J. Controlled Release 72, 217-224.
20. Harris, J. M., Martin, N. E., and Modi, M. (2001) Pegylation: a novel process for modifying pharmacokinetics. Clin. Pharmacokinet. 40, 539-551.
21. Kozlowski, A., Charles, S. A., and Harris, J. M. (2001) Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 15, 419-429.
22. Conover, C. D., Greenwald, R. B., Pendri, A., Gilbert, C. W., and Shum, K. L. (1998) Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother. Pharmacol. 42, 407-414.
23. Greenwald, R. B. (2001) PEG drugs: an overview. J. Controlled Release 74, 159-71.
24. Greenwald, R. B., Choe, Y. H., McGuire, J., and Conover, C. D. (2003) Effective drug delivery by PEGylated drug conjugates. Adv. Drug Delivery Rev. 55, 217-250.
25. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54, 459-476.
26. Gunaseelan, S., Debrah, O., Wan, L., Leibowitz, M. J., Rabson, A. B., Stein, S., and Sinko, P. J. (2004) Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay. Bioconjugate Chem. 15, 1322-1333.
27. Wan, L., Zhang, X., Gunaseelan, S., Pooyan, S., Debrah, O., Leibowitz, M. J., Rabson, A. B., Stein, S., and Sinko, P. J. (2006) Novel multi-component nanopharmaceuticals derived from poly-( ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects. AIDS Res. Ther. 3, 12.
28. Harris, J. M. (1991) Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, Plenum Press, New York.
29. Sherman, M. R., Williams, L. D., Saifer, M. C. P., French, J. A., Kwak, L. W., and Oppenheim, J. J. (1997) Conjugation of High, Molecular Weight Poly(ethylene glycol) to Cytokines: Granulocyte-Macrophage Colony Stimulating Factors As Model Substrates., ACS, Washington, DC.
30. Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., and Amidon, G. L. ( 1997) The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm. Res. 14, 1568-1573.
31. Prabha, S., Zhou, W. Z., Panyam, J., and Labhasetwar, V. (2002) Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int. J. Pharm. 244, 105-115.
32. Nakai, T., Kanamori, T., Sando, S., and Aoyama, Y. (2003) Remarkably size-regulated cell invasion by artificial viruses. Saccharide-dependent self-aggregation of glycoviruses and its consequences in glycoviral gene delivery. J. Am. Chem. Soc. 125, 8465-8475.
33. Osaki, F., Kanamori, T., Sando, S., Sera, T., and Aoyama, Y. (2004) A quantum dot conjugated sugar ball and its cellular uptake. On the size effects of endocytosis in the subviral region. J. Am. Chem. Soc. 126, 6520-6521.
34. Caliceti, P., and Veronese, F. M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Delivery Rev. 55, 1261-1277.
35. Arendshorst, W. J., and Navar, L. G. (1988) Renal Circulation and Glomerular Hemodynamics, Brown, Boston, MA.